MedTrace Logo

Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.

NCT02606916 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-09-04

No results posted yet for this study

Summary

This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.

Conditions

Interventions

RADIATION

SMART

Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )

DRUG

DDP

DDP(25 mg/m2.qw) for six weeks.

DRUG

S-1

S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Hui Liu, Professor · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02606916 on ClinicalTrials.gov